TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Glucose and Lipid Metabolism on Antipsychotic Medication

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 18-60 years~* Patients: otherwise healthy and meets DSM-IV criteria for schizophrenia or schizoaffective disorder, any type, treated with haloperidol, olanzapine, clozapine, quetiapine, ziprasidone, aripiprazole, or risperidone for at least 3 months~* Controls: healthy~* Able to give informed consent~* No antipsychotic medication changes for 3 months, and no other medication changes for 2 weeks prior to Baseline Evaluations.~Exclusion Criteria:~* Axis I psychiatric disorder criteria met in self except for substance use disorders as below~* Patients and controls: meets DSM-IV criteria for the diagnoses of substance abuse within the past 3 months~* Involuntary legal status (as per Missouri law)~* The presence of any serious medical disorder that may confound the assessment of relevant biologic measures or diagnosis, including: significant organ system dysfunction, metabolic diseases, type 1 diabetes mellitus, symptomatic type 2 diabetes mellitus (see below), pregnancy, endocrine disease, coagulopathy, clinically significant anemia, that would preclude blood sampling (as determined by the PI) or acute infection;~* Patients taking more than one atypical antipsychotic medication;~* Subjects taking certain prescription medications (as determined by PI on a case by case basis).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Olanzapine (Type: ACTIVE_COMPARATOR): Participants in this group were randomized to flexibly-dosed treatment with olanzapine.
- Risperidone (Type: ACTIVE_COMPARATOR): Participants in this group were randomized to flexibly-dosed treatment with risperidone.
- Quetiapine (Type: ACTIVE_COMPARATOR): Participants in this group were randomized to flexibly-dosed treatment with quetiapine.
- Ziprasidone (Type: ACTIVE_COMPARATOR): Participants in this group were randomized to flexibly-dosed treatment with ziprasidone.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Hepatitis B Vaccination on HBs Antigenemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HBV patients with persistent HBs antigenemia~Exclusion Criteria:~* decompensated liver cirrhosis~* hepatocellular carcinoma~* other causes of liver disease or mixed causes (excessive alcohol consumption,~* autoimmune liver disease~* immunosuppressive drugs~* infection with hepatitis C virus.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- chronic HBV with persistent HBsAg (Type: ACTIVE_COMPARATOR): inactive carriers (n=100). Group II: CHB exposed to nucleos(t)ides (n=120) till 6 months after HBe seroconversion and HBV DNA disappearance in HBeAg positive (n=60) or DNA disappearance in HBeAg negative patients (n=60). All showed persistent HBs antigenemia.~they were given 30 µg of HBV vaccine initiated 6 months after HBe seroconversion and disappearance of HBV DNA.
- control group (Type: NO_INTERVENTION): A control group (n=100) did not receive HBV vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Absorption, Metabolism and Excretion (AME) of Single Dose Radiolabeled Prucalopride Succinate in Volunteers

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Males aged between 18 and 50 years, inclusive~* Body mass index (BMI) of ≥18 and ≤30 kg/m2~* No more than 2 bowel movements per day or fewer than 3 bowel movement per week~* Provision of signed and dated, written informed consent prior to any study specific procedures~Exclusion Criteria:~* Have participated in a \[14C\]-study within the last 6 months.~* Exposure to clinically significant radiation within 12 months prior to dose (for example, serial X-ray or computed tomography scans, barium meal, current employment in a job requiring radiation exposure monitoring).~* Male subjects who consume more than 21 units of alcohol per week or 3 units per day.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Radiolabeled Prucalopride Succinate (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Japanese Patients With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria:~* Diagnosis of type 2 diabetes prior to informed consent~* Male and female patients on diet and exercise regimen for at least 12 weeks prior to informed consent who are:~  * drug-naïve, defined as no antidiabetic drugs for at least 12 weeks prior to informed consent or,~ * pre-treated with one oral antidiabetic drug (for sulfonylurea, with up to half of the maximum approved dose) on stable dosage for at least 12 weeks prior to the informed consent (for thiazolidinedione, therapy has to be unchanged for at least 18 weeks prior to the informed consent). Individual antidiabetic drug will have to be discontinued at Visit 1.~* haemoglobin A1c (HbA1c) at Visit 1 (screening)~  * for patients without antidiabetic therapy : HbA1c \>=8.0 to =\<10.5%~ * for patients with one oral antidiabetic drug : HbA1c \>=7.5 to =\<10.5%~* HbA1c \>=7.5 to =\<10.0% at Visit 4 for randomisation into the double blind treatment period~Exclusion criteria:~* Uncontrolled hyperglycaemia with a glucose level \>270 mg/dL (\>15.0 mmol/L) during the open label stabilisation period and placebo run in period~* Impaired renal function, defined as estimated glomerular filtration rate (eGFR) \<45 mL/min/1.73m2 (modification of diet in renal disease (MDRD) formula)~* Acute coronary syndrome, stroke or transient ischemic attack (TIA) within 12 weeks prior to informed consent~* Indication of liver disease, defined by serum levels of either alanine transaminase (ALT), aspartate transaminase (AST), or alkaline phosphatase (ALP) above 3 x upper limit of normal (ULN)

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- empagliflozin 10 mg + linagliptin 5 mg (Type: EXPERIMENTAL): patient to receive a tablet containing low dose empagliflozin and linagliptin once daily
- empagliflozin 10 mg (Type: EXPERIMENTAL): patient to receive a tablet containing low dose empagliflozin once daily
- empagliflozin 25 mg + linagliptin 5 mg (Type: EXPERIMENTAL): patient to receive a tablet containing high dose empagliflozin and linagliptin once daily
- empagliflozin 25 mg (Type: EXPERIMENTAL): patients to receive a tablet containing high dose empagliflozin once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DEVICE_FEASIBILITY
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participants with T1DM for at least 2 years and who have used an insulin delivery system with any rapid-acting insulin analog for the preceding 6 months~* Have a body mass index of 18.5 to 37 kilogram per meter squared~* Have a hemoglobin A1c level ≥6.0% and ≤9.0%~Exclusion Criteria:~* Have known allergies or history of hypersensitivity to insulin lispro~* Have had an episode of severe hypoglycemia within the past 6 months~* Have had more than 1 episode of diabetic ketoacidosis in the past 6 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- AID System Containing Insulin Lispro (Type: EXPERIMENTAL): The automated insulin delivery (AID) system is comprised of a continuous subcutaneous insulin infusion (CSII) pump component with a PLGS algorithm, and a continuous glucose monitor (CGM) component.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of the Efficacy and Safety of Sirolimus Versus Everolimus Versus Mycophenolate in Kidney Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Recipients, adults of the first living or deceased donor kidney transplant;~2. Patients who agreed to participate in the study and signed the informed consent form~Exclusion Criteria:~1. Receptors with a medical history of nephrotic syndrome or focal and segmental glomerulosclerosis confirmed as the etiology of end-stage renal disease;~2. Receptors with poor understanding about chronic kidney disease and its treatment alternatives;~3. Receptors with early history of non compliance to treatment with immunosuppressive drugs;~4. Retransplantation;~5. Multi-organ recipients;~6. Recipients with BMI\> 30 kg / m2;~7. KDPI\> 80%;~8. Cold ischemia time greater than 24 hours;~9. Receptors with a percentage of anti-HLA antibodies above 50%, either class I or Class II;~10. Women of childbearing potential who do not undertake contraceptive methods (condoms or oral contraceptives).~11. Patients receiving immunosuppressive therapy prior to transplantation, except low dose of prednisone;~12. Patients with severe uncontrolled dyslipidemia;~13. Patients who have a known contraindication for administration of any of the immunosuppressive drugs provided for in this study;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- sirolimus +tacrolimus (Type: EXPERIMENTAL): Patients will receive initial dose of 0,05 mg/kg BID oftacrolimus to reach blood trough concentration between 3-5 ng/mL. Initial dose of sirolimus of 3mg once a day to reach blood trough concentration between 4-8 ng/mL.
- everolimus +tacrolimus (Type: EXPERIMENTAL): Patients will receive initial dose of 0,05 mg/kg BID de tacrolimus to reach blood trough concentration between 3-5 ng/mL. Initial dose of 1.5 mg BID of everolimus to reach blood trough concentration between 4-8 ng/mL.
- mycophenolate +tacrolimus (Type: ACTIVE_COMPARATOR): Patients will receive initial dose of 0,1 mg/kg BID de tacrolimusto reach blood trough concentration between Fixed dose of mycophenolate (mycophenolate mofetil, 1 g BID or sodium mycophenolate, 720 mg BID).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Vitamin E in Preventing Contrast-Induced Acute Kidney Injury Following Coronary Angiography

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. All patients whon have either stable coronary artery disease (CAD) or recent acute coronary disease (ACS) and are scheduled for coronary angiography.~2. Patients who have eGFR ≤60 ml/min/1.73 m2~Exclusion Criteria:~1. Allergy to contrast media~2. Cardiogenic shock~3. Pulmonary edema~4. Overt cardiac failure or left ventricular ejection fraction ≤ 30%~5. Acute kidney injury~6. The history of receiving contrast media for any medical diagnostic or therapeutic procedures during previous 5 days~7. The history of dialysis~8. Being pregnant~9. Having recent acute myocardial infarction~10. Taking antioxidants and nephrotoxic drugs including NSAID and ACE-I on previous 2 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- Vit-E (Type: ACTIVE_COMPARATOR): 600 IU on 12 hours before angiography and 400 IU on 2 hours before angiography

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Sotagliflozin in Young Adult Patients With Type 1 Diabetes Mellitus and Elevated Hemoglobin A1C

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participant had given written informed consent.~* Young adult participants \>=18 to \<=30 years old at Screening, with a confirmed diagnosis of T1DM made at least 1 year prior to informed consent.~* Participants were being treated with insulin or insulin analogue delivered via continuous subcutaneous insulin infusion (CSII) or multiple daily injections (MDI).~* At Screening, must had A1C \>= 9.0%.~* Must be willing and able to perform self-monitored blood glucose (SMBG) and complete the study diary.~* Females of childbearing potential must use an adequate method of contraception and had a negative pregnancy test.~Exclusion Criteria:~* Any prior use of LX4211/sotagliflozin.~* Use of antidiabetic agent other than insulin or insulin analogue at the time of screening.~* Use of sodium-glucose cotransporter (SGLT) inhibitors within 8 weeks prior to start of the placebo Run-in Period.~* Chronic systemic corticosteroid use.~* Type 2 diabetes, or severely uncontrolled diabetes mellitus as determined by the Investigator.~* History of diabetic ketoacidosis (DKA) or nonketotic hyperosmolar state within 6 months prior to the Screening Visit.~* History of severe hypoglycemic event within 1 month prior to the Screening Visit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 30 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Two placebo-matching sotagliflozin tablets, once daily, orally, before the first meal of the day for 12 weeks.
- Sotagliflozin 400 mg (Type: EXPERIMENTAL): Sotagliflozin 400 milligram (mg) (two 200 mg tablets), once daily, orally, before the first meal of the day for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males With Active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, or Non-radiographic Axial Spondyloarthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Diagnosis of active rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis or, non-radiographic axial spondyloarthritis for at least 12 weeks prior to screening, meeting the corresponding specific disease classification criteria as specified in the protocol~Key Exclusion Criteria:~* Previously documented problems with male reproductive health~* Prior diagnosis of male infertility~* Use of any prohibited concomitant medication as outlined by protocol~Note: Other protocol-defined Inclusion/Exclusion criteria may apply.

- Gender: MALE
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Filgotinib (Type: EXPERIMENTAL): Participants received filgotinib 200 milligrams (mg) tablet, orally, once daily up to Week 13 in the double-blind (DB) phase. At Week 13, participants who were arthritis responders, were unblinded and received open-label (OL) treatment filgotinib 200 mg, tablet, orally, once daily up to approximately 143 weeks (until Week 156) in the extension (EXT) phase and participants who were arthritis nonresponders discontinued blinded study drug and started standard of care (SOC) treatment in the EXT phase. Participants on DB treatment or OL filgotinib who entered the monitoring phase (if their sperm parameters met ≥50% decrease threshold in pre-specified semen parameters) discontinued the study drug and started SOC for up to 52 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo (matched to filgotinib) tablet, orally, once daily up to Week 13 in the DB phase. At Week 13, participants were unblinded and started SOC treatment in the EXT phase for up to approximately 143 weeks (until Week 156). Participants who entered the monitoring phase (if their sperm parameters met ≥50% decrease threshold in pre-specified semen parameters) continued on SOC treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. Ratio-Study. (BY217/M2-112)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Main Inclusion Criteria:~* FEV1/FVC ratio (post-bronchodilator) ≤70%~* FEV1 (post-bronchodilator) ≤50% of predicted~* Current smoker or ex-smoker~* Clinically stable COPD indicated by no exacerbation and no change in COPD treatment of within 4 weeks prior to baseline~* Availability of a chest x-ray dated a maximum of 6 months prior to study baseline visit B0 or a willingness to have a chest x-ray performed before baseline~Main Exclusion Criteria:~* COPD exacerbation indicated by a treatment with systemic glucocorticoids not stopped 4 weeks prior to baseline~* Lower respiratory tract infection not resolved 4 weeks prior to baseline~* Diagnosis of asthma and/or other relevant lung disease~* Known alpha-1-antitrypsin deficiency~* Need for long-term oxygen therapy defined as ≥16 hours/day

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Effect on Body Weight of Leptin Administered in Conjunction With Pramlintide in Overweight and Obese Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Is obese (Body Mass Index \[BMI\]\>=30kg/m\^2 and \<=35kg/m\^2); or overweight (BMI\>=27kg/m\^2 and \<30kg/m\^2) with abdominal obesity, based on the following: \*waist circumference \>102 cm if male, \*waist circumference \>88 cm if female~* Is a nonsmoker (has not smoked for at least 6 months prior to the study)~* Consumes a morning and evening meal each day~Exclusion Criteria:~* Is diagnosed with type 2 diabetes~* Is currently enrolled or plans to enroll in a diet, weight loss, or exercise program with the specific intent of losing weight (subjects who have been following an exercise regimen resulting in stable weight maintenance for at least 2 months prior to enrollment are eligible for study inclusion)~* Has been treated over the past 2 months, is currently treated, or is expected to require or undergo treatment with any of the following medications: \*antiobesity agents (prescription or over-the-counter), \*antipsychotic agents, \*antiepileptic agents, \*antidepressant agents, \*drugs that directly affect gastrointestinal motility~* Has received any investigational drug within 30 days or within a period corresponding to 5 half-lives of that drug, whichever is greater, prior to this study starting~* Has previously received treatment with recombinant leptin or pramlintide

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Placebo and Metreleptin (Type: EXPERIMENTAL): Placebo-pramlintide 600 microliters (µL) twice a day (BID) and metreleptin (recombinant-methionyl human leptin) 5 milligram (mg) BID, 20 weeks
- Pramlintide Acetate and Placebo (Type: EXPERIMENTAL): Lead-in period: 2 weeks pramlintide acetate 180 mcg BID, then 2 weeks pramlintide acetate 360 mcg BID Study period: Pramlintide acetate 360 mcg BID and placebo-metreleptin 1 mL BID, 20 weeks
- Pramlintide Acetate and Metreleptin (Type: EXPERIMENTAL): Lead-in period: 2 weeks pramlintide acetate 180 mcg BID, then 2 weeks pramlintide acetate 360 mcg BID Study period: Pramlintide acetate 360 mcg BID and metreleptin (recombinant-methionyl human leptin) 5 mg BID, 20 weeks
- Lead-In Period (Type: OTHER): During the Lead-In Period before a participant was randomized to a study arm, the participant received 180 mcg pramlintide acetate twice a day (BID) for 2 weeks, followed by 360 mcg pramlintide acetate BID for 2 weeks (total of 4 weeks in the Lead-In Period).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with Cutaneous T-cell Lymphoma (Stage 1B or higher)~* Age: over 18 years of age~* Have the ability to swallow capsules.~* You must be at least 3 weeks from any prior chemotherapy or anticancer therapy treatment and have recovered from any side effects of that treatment.~* Patients also require adequate heart, liver, and kidney function.~Exclusion Criteria:~* Pregnant and nursing women and those with known allergy to the study drug are excluded from this study.~* Patients are excluded if they are currently receiving chemotherapy, radiation therapy, or other investigational anti-cancer therapy.~* Patients diagnosed with HIV, active hepatitis or who require intravenous antibiotics or antifungal agents are not permitted.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete